Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section

Online Activities

                                                                                                                                                                                                                                                  

Rodriguez_Photo.jpg

 Use of Disease-Modifying Therapies in Multiple
 Sclerosis: A Review for the Specialty Pharmacist

  Available through: Dec 15, 2018

  Target Audience: Pharmacists

  Approved for: 1.75 Contact Hours  

  Faculty: Ryan Rodriguez PharmD, BCPS

  Cost: $10

ActivityAnnouncement_Use of Disease Modifying Therapies in Multiple Sclerosis.pdf

                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

Mike Gabay-1-2_0.jpg

 Targeted Therapies for Lipid Disorders: A Review for
 the Specialty Pharmacist

  Available through: Dec 31, 2018

  Target Audience: Pharmacists 

  Approved for: 1.0 Contact Hours  

  Faculty: Michael Gabay PharmD, JD, BCPS

  Cost: $10

ActivityAnnouncement_Targeted Therapies for Lipid Disorders.pdf

 

Joint Providership with National Kidney Foundation

logo.png

Please be sure to check out these activities sponsored by UIC and the National Kidney Foundation. https://www.kidney.org/professionals/KLS/cmeprograms


The Potassium Challenge in CKD: Managing Acute & Chronic Hyperkalemia (A Knowledge-Based Activity)

Potassium Challenge in CKD.jpg

Available through: Jun 26, 2017

This CME/CE Activity focuses on the pathophysiologic consequences of hyperkalemia, the limitations of current therapeutic strategies, and the risks associated with suboptimal dosing or discontinuation of RAAS therapy as a result of persistent hyperkalemia.

Approved for: 1.5

Faculty: Robert D. Toto, MD; Peter McCullough, MD, MPH, FNKF; Kamyar Kalantar-Zedeh, MD, MPH, PhD

Cost: Free for members and non-members

Click here for more information or to participate in this Activity.

Pathogenesis and Management of Nephrotic Syndrome in Primary Podocytopathies (A Knowledge-Based Activity)

Pathogenesis and Management of Nephrotic Syndrome.jpg

Available through: Jun 26, 2017

This CME/CE Activity will address the ongoing medical problem of nephrotic syndrome, including the management of proteinuria. Content will review the pathogenesis and etiologies of nephrotic syndrome. Evaluation, management strategies, and treatment options will also be addressed.

Approved for: 1.5 

Faculty: Laurence Beck, MD, PhD, Brad Rovin, MD, Fernando Fervenza, MD, PhD

Click here for more information or to participate in this Activity.
 

CKDinform: Early Detection and Prevention (A Knowledge-Based Activity)

CKDInform.jpg

Available through: Jul 01, 2017

This activity will address the evaluation and management of chronic kidney disease (CKD) within the primary care setting. The burden of CKD to the population, modifiable CKD risk factors, and vital screening methods and interpretation of test results will be discussed. Evidence-based treatment recommendations and management plans for CKD will be presented. Topics will also include indications for renal replacement therapy and referral and education for patients with progressive CKD.

Approved for: 1.5 

Faculty: Kirk Campbell, MD; Alexis Chettiar, RN, MSN, ACNP-BC; Sumeska Thavarajah, MD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

Management Strategies for Secondary Hyperparathyroidism in CKD: Vitamin D Supplementation (A Knowledge-Based Activity)

Management Strategies for Secondary Hyperparathyroidism.jpg

Available through: Jul 12, 2017

This activity will address the clinical challenge of preventing and treating secondary hyperparathyroidism (SHPT) in patients with CKD. Content will include an update on vitamin D, and will discuss the pathophysiology and consequences of SHPT. Expert faculty will also explore current and emerging strategies for the management of SHPT in CKD.

Approved for: 1.

Faculty: Myles Wolf, MD, MMSc; Glenville Jones, PhD; Ishir Bhan, MD, MPH; Michael Melamed, MD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

Improving Global Outcomes in Patients with Hepatitis C Infection in Late Stage Chronic Kidney Disease (A Knowledge-Based Activity)

Improving Global Outcomes.jpg

Available through: Jul 12, 2017

This activity will address the management of hepatitis C virus (HCV) in patients with advanced chronic kidney disease (CKD). Screening and treatment will be discussed. Clinical evidence for novel antivirals will also be included.

Approved for: 1.5

Faculty: Matthew Weir, MD; David Roth, MD; Roy Bloom, MD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

CKD-MBD: State-of-the-Art Considerations for Optimal Outcomes (A Knowledge-Based Activity)

CKD MBD State of the Art Considerations.jpg

Available through: Jul 12, 2017

This activity will address the most recent developments in understanding and managing chronic kidney disease-mineral and bone disorder (CKD-MBD). Expert faculty will discuss new insights regarding pathogenesis, along with best practice options for diagnosis and treatment.

Approved for: 1.5 

Faculty: Rajnish Mehrotra, MD, MS, FNKF; Ranjani Moorthi, MD, MBBS, MPH, MS; Francesca Tentori, MD, MS

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

Urgent and Non-Urgent Hyperkalemia (A Knowledge-Based Activity)

Uregent and NonUrgent Hyperkalemia.jpg

Available through: Aug 17, 2017

This activity will address the some of the considerations that inform clinical judgments essential to the evaluation and management of hyperkalemia as encountered in the outpatient arena. Program content includes a review of the cellular mechanisms that normally ensure potassium homeostasis, how these are affected by RAAS inhibitors, hyperkalemic risk assessment based on clinical trials, and characteristics of the ideal, current and emerging oral ion exchangers.

Approved for: 1.5

Faculty: Ishir Bhan, MD, MPH; Linda Fried, MD, MPH, FNKF; Csaba Kovesdy, MD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

Nephropathic Cystinosis: New Insights and Approaches to Care

Nephropathic Cystinosis.jpg

Available through: Sep 21, 2017

This activity will address the pathogenesis and management of nephropathic cystinosis (NC). Recognition, evaluation, diagnosis, and treatment will be discussed. Evidence-based management strategies, clinical evidence for available treatment options, and possible directions of future research, will also be included.

Approved for: 1.0 

Faculty: Craig B. Langman, MD; Sandra Amaral, MD, MHS; Frederick Kaskell, MD, PhD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

CKD-Related Anemia and Cardiovascular Disease: What Does the Future Hold? (A Knowledge-Based Activity)

CKD Related Anemia.jpg

Available through: Sep 21, 2017

This activity will address the common medical problem of CKD related anemia and the risk of cardiovascular events. The benefits and limitations of established anemia therapies will be discussed, as well as emerging strategies for anemia management. 

Approved for: 1.0 

Faculty: Steven Fishbane, MD; Peter McCullough, MD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

Evidence-Based Use of Growth Hormone in Chronic Kidney Disease: A Quality Improvement Initiative for Optimizing Outcomes (An Application-Based Activity)

Evidence Based Use of Growth Hormone.jpg

Available through: Nov 16, 2017

This web-based interactive virtual patient activity focuses on the issue of growth failure as a result of growth hormone dysfunction in chronic kidney disease (CKD).  Participants have the opportunity to review an expert discussion on the treatment of growth failure in CKD, with an emphasis on the role of growth hormone therapy in improving outcomes.  Recommendations for appropriate use of growth hormone therapy are presented, along with two virtual patient case studies through which participants learn how to assess, monitor, and treat patients with growth failure in CKD.     

Approved for: 1.5 

Faculty: Bradley A. Warady, MD; John D. Mahan, MD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.
 

Chronic Kidney Disease - Mineral Bone Disorder: Implications for Cardiac Outcomes (An Application-Based Activity)

CKD MBD Cardiac Outcomes.jpg

 




 


Available through: Dec 16, 2017

 This professional educational activity will address the common medical problem of CKD-MBD and the  implications for cardiac outcomes. Content will review new data related to CKD-MBD published since the  2009 KDIGO guideline on CKD-MBD. Strategies to improve patient adherence and the implications of  calcium levels in CKD will also be presented. Finally, the relationship between CKD-MBD and CVD and  the opportunity to improve treatment and develop strategies to improve patient management and outcomes  will be explored. A case study approach will facilitate application of learning to clinical practice.   

Approved for: 1.0 Credit Hours

Faculty: Geoffrey Block, MD; Kamyar Kalantar-Zadeh, MD, MPH, PhD

Cost: Free for NKF Members and non-members

Click here for more information or to participate in this Activity.

Top